Evidence map›Paper›PMID 33502828›Full record

ReviewThe Kaohsiung journal of medical sciences2021

Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapies.

Jonggi Choi, Young-Suk Lim

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Kaohsiung journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Prevention in Hepatology.Journal of personalized medicine · 2024
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jonggi ChoiDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID https://orcid.org/0000-0002-7470-5850
Young-Suk LimDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID https://orcid.org/0000-0002-1544-577X
Ulsan College · KR

Funding

Gilead Sciences
6 · The paper itself

Abstract

Over the past decades, marked advancement has been made in the prevention and treatment of hepatitis B virus (HBV) infection. Due to highly effective antiviral therapies for chronic hepatitis B (CHB), long-term clinical outcomes in patients with CHB has also been dramatically improved. However, current antiviral therapies for CHB cannot completely abolish the risk of hepatocellular carcinoma (HCC). In addition, current treatment guidelines for CHB should be interpreted with caution given that HBV-associated hepatocarcinogenesis could be underway in patients who are not eligible for antiviral therapies by current guidelines. Therefore, efforts to reconcile treatment guidelines with recent clinical evidence should be made for reducing further development of HCC. In this article, we review the secondary prevention of HBV-related HCC with current antiviral therapies.

Indexed as

Antiviral AgentsCarcinogenesisCarcinoma, HepatocellularDNA, ViralHepatitis B, ChronicHepatitis B virusLiver NeoplasmsPractice Guidelines as TopicRecurrenceRisk FactorsSecondary PreventionViral Hepatitis VaccinesAntiviral AgentsDNA, ViralViral Hepatitis Vaccinesdisease burdenhepatitis B virushepatocellular carcinoma

Identifiers

PMID33502828
PMCPMC11896461
OpenAlexW3123174067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.